DXB.ASX: Dimerix Receives US$10M Upfront Payment from Everest

Dimerix Receives US$10M Upfront Payment from Everest

Stock	Dimerix Ltd (DXB.ASX)
Release Time	20 Aug 2026, 9:13 a.m.
Price Sensitive	Yes

This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA. The summaries are generated by large language models so please interpret with care.

Dimerix Secures US$10M Upfront from Everest for DMX-200 Licensing

Key Points

Dimerix receives US$10 million upfront from Everest
Everest gains exclusive rights for DMX-200 in key Asian markets
Dimerix eligible for additional US$330 million in milestone payments

Full Summary

Dimerix Ltd, a clinical-stage biopharmaceutical company, has announced receiving an initial US$10 million upfront payment from Everest Medicines for the commercial licensing of DMX-200, a treatment for Focal Segmental Glomerulosclerosis (FSGS). Everest Medicines has been granted exclusive rights to develop and commercialize DMX-200 in Greater China, South Korea, and Southeast Asia. Dimerix stands to receive up to an additional US$330 million in milestone payments and tiered royalties based on DMX-200's net sales in these regions. This partnership marks the fifth regional license agreement for DMX-200, expanding Dimerix's global commercialization strategy.

Guidance

Dimerix eligible for up to US$330 million in milestone payments

Outlook

Dimerix is optimistic about the potential of DMX-200 in treating FSGS and is advancing towards global registration and commercialization.